Groupe de Recherche et d’Action pour la Santé
Accueil > Infos diverses > MSF challenges Gilead’s patent application for hepatitis C combination (...)

MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices (MSF)

vendredi 29 décembre 2017

Geneva, 18 December 2017 – The international medical humanitarian organisation, Médecins Sans Frontières (MSF) has filed a legal patent challenge in China against US pharmaceutical corporation Gilead’s patent application for the combination of two crucial oral hepatitis C medicines, sofosbuvir and velpatasvir. This combination is the first direct-acting antiviral (DAA) treatment to be registered for use against all genotypes of the disease. Rejection of patents for this combination would pave the way towards the availability of affordable generic versions of this treatment that millions of people need in China and around the world.

Voir en ligne : MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices

SPIP | squelette | | Plan du site | Suivre la vie du site RSS 2.0 | © GRAS asbl 2012